Day: June 24, 2024

London, June 24, 2024 (GLOBE NEWSWIRE) — June 24, 2024, London, UK – OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine learning (ML) solutions provider that will work exclusively with OPEN Health. This alliance will see fusion’s market-leading AI capabilities deployed across OPEN Health’s extensive global client base, which includes 49 of the top 50 pharmaceutical companies.

Mary McGregor, Founder of fusion, commented, “OPEN Health provides an unrivalled platform to expand the AI agenda globally in our sector. Our longstanding relationship with OPEN Health leadership facilitated early conversations, enabling us to quickly market-test joint solutions, which led to a swift and unanimous decision to formalize this collaboration. This partnership empowers us to redefine the boundaries of what AI can accomplish in healthcare.”

Margot Hannah,  Chief Executive Officer of Scientific Communications at OPEN Health, expressed her enthusiasm for the partnership: “We immediately recognized the need to expand our capabilities and started a dialog with fusion about an exclusive partnership to provide pioneering solutions that integrate OPEN Health’s capabilities with fusion’s cutting-edge expertise in AI and ML. Fusion’s expertise in this area is unparalleled, and we are excited about the possibilities this partnership brings for our clients.”

Steve Duryee, Chief Operating and Transformation Officer at OPEN Health, added, “We are committed to harnessing the power of cutting-edge technologies, including AI, ML, robotic process automation, and data analytics, to drive higher value and improved outcomes for our clients. With the recent launch of our Solutions Innovation Center, and the addition of fusion to our extended team of elite-level technology partners, we are now in the pole position to deliver the most innovative, technologically advanced solutions to our biopharmaceutical partners.”

By integrating with fusion’s advanced technology, OPEN Health underscores its commitment to leading the AI agenda with socially beneficial innovations to drive innovation and efficiency for clients. Contact OPEN Health to set up an interactive demonstration at www.openhealthgroup.com/contact-us.

About OPEN Health
OPEN Health unites world-class scientific, strategic, and creative expertise to solve complex challenges for global biopharma. We are a flexible, global organization, creating high-performing strategic partnerships with our clients. We embrace our different perspectives and strengths to deliver innovative solutions that have a positive impact on commercial and patient outcomes. OPEN Health unlocks possibilities across consulting, HEOR and market access, scientific communications, and patient engagement. To learn more, visit www.openhealthgroup.com.

About fusion
fusion specializes in delivering AI and ML solutions. Known for its advanced technology and innovative approach, fusion aims to transform the pharmaceutical industry by integrating AI-first solutions. To learn more, visit www.fusionagency.solutions.

Attachment

• OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications

Candice Subero
OPEN Health
candicesubero@openhealthgroup.com

GlobeNewswire Distribution ID 9157597

London, June 24, 2024 (GLOBE NEWSWIRE) — June 24, 2024, London, UK – OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine learning (ML) solutions provider that will work exclusively with OPEN Health. This alliance will see fusion’s market-leading AI capabilities deployed across OPEN Health’s extensive global client base, which includes 49 of the top 50 pharmaceutical companies.

Mary McGregor, Founder of fusion, commented, “OPEN Health provides an unrivalled platform to expand the AI agenda globally in our sector. Our longstanding relationship with OPEN Health leadership facilitated early conversations, enabling us to quickly market-test joint solutions, which led to a swift and unanimous decision to formalize this collaboration. This partnership empowers us to redefine the boundaries of what AI can accomplish in healthcare.”

Margot Hannah,  Chief Executive Officer of Scientific Communications at OPEN Health, expressed her enthusiasm for the partnership: “We immediately recognized the need to expand our capabilities and started a dialog with fusion about an exclusive partnership to provide pioneering solutions that integrate OPEN Health’s capabilities with fusion’s cutting-edge expertise in AI and ML. Fusion’s expertise in this area is unparalleled, and we are excited about the possibilities this partnership brings for our clients.”

Steve Duryee, Chief Operating and Transformation Officer at OPEN Health, added, “We are committed to harnessing the power of cutting-edge technologies, including AI, ML, robotic process automation, and data analytics, to drive higher value and improved outcomes for our clients. With the recent launch of our Solutions Innovation Center, and the addition of fusion to our extended team of elite-level technology partners, we are now in the pole position to deliver the most innovative, technologically advanced solutions to our biopharmaceutical partners.”

By integrating with fusion’s advanced technology, OPEN Health underscores its commitment to leading the AI agenda with socially beneficial innovations to drive innovation and efficiency for clients. Contact OPEN Health to set up an interactive demonstration at www.openhealthgroup.com/contact-us.

About OPEN Health
OPEN Health unites world-class scientific, strategic, and creative expertise to solve complex challenges for global biopharma. We are a flexible, global organization, creating high-performing strategic partnerships with our clients. We embrace our different perspectives and strengths to deliver innovative solutions that have a positive impact on commercial and patient outcomes. OPEN Health unlocks possibilities across consulting, HEOR and market access, scientific communications, and patient engagement. To learn more, visit www.openhealthgroup.com.

About fusion
fusion specializes in delivering AI and ML solutions. Known for its advanced technology and innovative approach, fusion aims to transform the pharmaceutical industry by integrating AI-first solutions. To learn more, visit www.fusionagency.solutions.

Attachment

• OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications

Candice Subero
OPEN Health
candicesubero@openhealthgroup.com

GlobeNewswire Distribution ID 9157597

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South Africa. EXBLIFEP® has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of severe infections earlier in 2024.

Saint-Louis, France and Weil am Rhein, Germany and Zurich, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) — Allecra Therapeutics (“Allecra”) and Acino today announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP^® (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024. In addition, the companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in the above territories.

“Acino has established itself as a leader in South Africa and the GCC region. They are an ideal partner to support us as we build towards commercialisation of EXBLIFEP^® following our regulatory approvals in the US and EU,” stated Andreas Kranzusch, Chief Financial Officer and Managing Director at Allecra Therapeutics. “This agreement reflects the understanding that there remains a significant global need to address the dangerous increase of resistance to standard-of-care antibiotics, and we look forward to working with Acino to address this.”

“At Acino, we are dedicated to providing novel healthcare solutions to physicians and patients, aiming to alleviate the health burden in emerging markets. We are incredibly excited to partner with Allecra to offer access to this innovative product in two key geographic regions and, potentially, beyond,” said Andrew Bird, CEO (ai) at Acino. “We are committed to expediting the registration process in these designated markets to ensure hospitals’ swift access to EXBLIFEP^® as they continue to fight against high-risk infectious diseases in patients.”

About EXBLIFEP^® (cefepime/enmetazobactam)

EXBLIFEP^® is an intravenous antibiotic fixed-dose combination of enmetazobactam, a novel extended-spectrum β-lactamase inhibitor belonging to the penicillanic acid sulfone class, with the fourth-generation cephalosporin cefepime. Enmetazobactam has been shown to restore the efficacy of cefepime against some multi-drug resistant bacteria, including ESBL-producing pathogens alone or in combination with some resistant β-lactamase mutations as OXA-48 or AmpC, which are increasing in Europe and for which there are few therapeutic alternatives.

EXBLIFEP^® demonstrated statistically significant superior overall treatment success in Allecra’s pivotal Phase III ALLIUM trial, which compared 1034 randomized patients receiving either cefepime 2 g/enmetazobactam 0.5 g or piperacillin 4 g/tazobactam 0.5 g every 8 h as 2 h continuous intravenous infusion in a multi-centre, randomized, controlled, double-blind, global study in 112 sites within nineteen countries.

In February 2024, the U.S. Food and Drug Administration (FDA) approved EXBLIFEP^® as a treatment for complicated urinary tract infections (cUTI), including pyelonephritis, in patients 18 years and older. In March 2024 the European Commission (EC) granted marketing authorisation for EXBLIFEP^® for the treatment of adult patients with cUTI, including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); and bacteraemia that occurs in association with, or is suspected to be associated with any of the infections listed previously.

About Allecra Therapeutics

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate EXBLIFEP^® (cefepime/enmetazobactam), has successfully completed a randomized, controlled, double-blind, global Phase 3 trial compared to standard of care in patients with complicated urinary tract infections (cUTIs). Based on these results, the company has received FDA marketing approval in the U.S. and announced approval in the European Union for EXBLIFEP^® earlier this year.

Allecra has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors include Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace. Please visit www.allecra.com for further information.

About Acino

Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information, please visit www.acino.swiss.

Acino is part of Arcera, a global company in the life sciences sector headquartered in Abu Dhabi, United Arab Emirates. Arcera was established by ADQ, an Abu Dhabi-based investment and holding company, to build a global life sciences powerhouse poised to make significant contributions to realising the UAE’s aspiration to emerge as a frontrunner in science and technology. To learn more about Arcera, please visit www.arceralifesciences.com.

Attachments

• Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
• Acino and Allecra Therapeutics

For Allecra Therapeutics:
Andreas Kranzusch, Chief Financial Officer and Managing Director
ir@allecra.com

Gretchen Schweitzer, Trophic Communications, +49 172 8618540
allecra@trophic.eu

For Acino: 
Larisa Bernstein, Global Head of Communications
larisa.bernstein@acino.swiss

GlobeNewswire Distribution ID 9157528